Monalizumab is a first-in-class immune checkpoint inhibitor targeting natural killer group 2A (NKG2A), and is used for research in head and neck squamous cell carcinoma (HNSCC); it may restore broad anti-tumor responses mediated by NK and T cells and enhance the cytotoxic potential of other therapeutic antibodies.